Merrick I. Ross

Active 1990–2025

Also published as
Merrick I Ross
212
Papers
51,212
Citations
116
h-index
210
i10-index

Citations

Citations per year for Merrick I. Ross1974: 1 citations1993: 2 citations1994: 3 citations1995: 7 citations1996: 18 citations1997: 30 citations1998: 53 citations1999: 92 citations2000: 138 citations2001: 158 citations2002: 221 citations2003: 278 citations2004: 273 citations2005: 299 citations2006: 367 citations2007: 299 citations2008: 284 citations2009: 310 citations2010: 342 citations2011: 380 citations2012: 304 citations2013: 302 citations2014: 290 citations2015: 271 citations2016: 265 citations2017: 267 citations2018: 341 citations2019: 1,196 citations2020: 1,214 citations2021: 1,027 citations2022: 904 citations2023: 770 citations2024: 1,222 citations2025: 613 citations2026: 18 citations1975–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,287 citing papers, 30.9% of this breakdownChina: 1,076 citing papers, 7.8% of this breakdownGermany: 820 citing papers, 5.9% of this breakdownUnited Kingdom: 805 citing papers, 5.8% of this breakdownItaly: 734 citing papers, 5.3% of this breakdownAustralia: 701 citing papers, 5% of this breakdownNetherlands: 655 citing papers, 4.7% of this breakdownFrance: 549 citing papers, 4% of this breakdownCanada: 423 citing papers, 3% of this breakdownSwitzerland: 338 citing papers, 2.4% of this breakdownSpain: 331 citing papers, 2.4% of this breakdownJapan: 281 citing papers, 2% of this breakdown
0%30.9%Other 20.8%

Fields

  • Medicine59.5%
  • Biochemistry, Genetics and Molecular Biology30.3%
  • Immunology and Microbiology6.5%
  • Engineering1.6%
  • Computer Science0.5%
  • Agricultural and Biological Sciences0.2%
  • Other1.4%

Topics

  • Cutaneous Melanoma Detection and Management9.7%
  • Cancer Immunotherapy and Biomarkers7.3%
  • Immunotherapy and Immune Responses6%
  • CAR-T cell therapy research5.4%
  • Breast Cancer Treatment Studies5.2%
  • Melanoma and MAPK Pathways5.2%
  • Other61.2%

Coauthors

All papers

Open in search
  1. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James Warneke, Alexandra P. Ikeguchi, Jose Eugenio Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy C. Hsueh, Kim Margolin, Warren Chow, Kenneth F. Grossmann, Eliana Dietrich, Víctor G. Prieto, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa A. Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas - New England Journal of Medicine 2023 cited by 827

  2. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mohamed A. Jamal, Erez N. Baruch, Eva Pérez‐Guijarro, Chi‐Ping Day, Glenn Merlino, Barbara Pazdrak, Brooke S. Lochmann, Robert Szczepaniak‐Sloane, Reetakshi Arora, Jaime Anderson, Chrystia M. Zobniw, Eliza Posada, Elizabeth Sirmans, Julie M. Simon, Lauren E. Haydu, Elizabeth M. Burton, Linghua Wang, Minghao Dang, Karen Clise-Dwyer, Sarah Schneider, Thomas Chapman, Nana-Ama A.S. Anang, Sheila Duncan, Joseph Toker, Jared Malke, Isabella C. Glitza, Rodabe N. Amaria, Hussein A. Tawbi, Adi Diab, Michael K. Wong, Sapna P. Patel, Scott E. Woodman, Michael A. Davies, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, V. Behrana Jensen, Yardena Samuels, Ravid Straussman, Nadim J. Ajami, Kelly C. Nelson, Luigi Nezi, Joseph F. Petrosino, P. Andrew Futreal, Alexander J. Lazar, Jianhua Hu, Robert R. Jenq, Michael T. Tetzlaff, Yan Yan, Wendy S. Garrett, Curtis Huttenhower, Padmanee Sharma, Stephanie S. Watowich, James P. Allison, Lorenzo Cohen, Giorgio Trinchieri, Carrie R. Daniel, Jennifer A. Wargo - Science 2021 cited by 932

  3. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 2,598

  4. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

    Authors: , , , , , , , , , , , , , , - CA A Cancer Journal for Clinicians 2017 cited by 2,286

  5. Neoadjuvant relatlimab and nivolumab in resectable melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sapna P. Patel, Adi Diab, Anthony Lucci, Víctor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte E. Ariyan, Hussein A. Tawbi - Nature 2022 cited by 332

  6. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Liberty Posada, Lauren E. Haydu, Linghua Wang, Shaojun Zhang, Alexander J. Lazar, Courtney W. Hudgens, Vancheswaran Gopalakrishnan, Alexandre Reuben, Miles C. Andrews, Christine N. Spencer, Víctor G. Prieto, Padmanee Sharma, James P. Allison, Michael T. Tetzlaff, Jennifer A. Wargo - Nature Medicine 2018 cited by 826

  7. Final Version of 2009 AJCC Melanoma Staging and Classification

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 4,570

  8. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 617

  9. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2018 cited by 270

  10. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

    Authors: , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2023 cited by 89

  11. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Evan Wuthrick, Nicole R. McMillian, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2021 cited by 337

  12. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , - Nature Medicine 2021 cited by 148

  13. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Guang R. Gao, Hiya Banerjee, Mike Lau, Jeffrey E. Gershenwald, Anthony Lucci, Emily Z. Keung, Merrick I. Ross, Laura Pala, Eleonora Pagan, Rossana Lazcano Segura, Qian Liu, Mikayla Borthwick, Eric Lau, Melinda S. Yates, Shannon N. Westin, Khalida Wani, Michael T. Tetzlaff, Lauren E. Haydu, Mikhila Mahendra, Xiao-Yan Ma, Christopher J. Logothetis, Zachary Kulstad, Sarah B. Johnson, Courtney W. Hudgens, Ningping Feng, Lorenzo Federico, Georgina V. Long, P. Andrew Futreal, Swathi Arur, Hussein A. Tawbi, Amy E. Moran, Linghua Wang, Timothy P. Heffernan, Joseph R. Marszalek, Jennifer A. Wargo - Nature 2022 cited by 130

  14. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher Toth, Renjith Ramachandran, Seth Wardell, Audrey M. Gonzalez, Patrick Hwu - Clinical Cancer Research 2012 cited by 433

  15. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander M.M. Eggermont, Michael A. Davies, Miles C. Andrews, Donald A. Berry, Matthew S. Block, Genevieve M. Boland, Kathryn Bollin, Matteo S. Carlino, Richard D. Carvajal, Jonathan Cohen, Diwakar Davar, Keith A. Delman, Reinhard Dummer, Michael D. Farwell, David E. Fisher, Alberto Fusi, Isabella C. Glitza, Tanja D. de Gruijl, David Gyorki, Axel Hauschild, Tina J. Hieken, James Larkin, David H. Lawson, Célèste Lebbé, Jeffrey E. Lee, Michael Lowe, Jason J. Luke, Grant A. McArthur, David F. McDermott, Jennifer L. McQuade, Tara C. Mitchell, Teresa M. Petrella, Peter A. Prieto, Igor Puzanov, Caroline Robert, April K.S. Salama, Shaneen Sandhu, Dirk Schadendorf, Alexander N. Shoushtari, Jeffrey A. Sosman, Susan M. Swetter, Ken K Tanabe, Samra Turajlic, Douglas S. Tyler, Scott E. Woodman, Frances C. Wright, Jonathan S. Zager, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Jennifer A. Wargo, Christian U. Blank, Hussein A. Tawbi, Georgina V. Long - The Lancet Oncology 2019 cited by 218

  16. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elizabeth M. Burton, Sangeetha M. Reddy, Padmanee Sharma, James P. Allison, Phillip Andrew Futreal, Scott E. Woodman, Michael A. Davies, Jennifer A. Wargo - The Lancet Oncology 2018 cited by 290

  17. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Isabella C. Glitza, Hussein A. Tawbi, Michael K. Wong, Suzanne Cain, Merrick I. Ross, Jeffrey E. Lee, Jeffrey E. Gershenwald, Anthony Lucci, Richard E. Royal, Janice N. Cormier, Jennifer A. Wargo, Laszlo Radvanyi, Carlos A. Torres‐Cabala, Rameen Beroukhim, Patrick Hwu, Rodabe N. Amaria, Chantale Bernatchez - Clinical Cancer Research 2018 cited by 135

  18. Ethnic Differences Among Patients With Cutaneous Melanoma

    Authors: , , , , , , , - Archives of Internal Medicine 2006 cited by 379

  19. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2001 cited by 2,401

  20. Lymphedema beyond breast cancer

    Authors: , , , , , - Cancer 2010 cited by 512

  21. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the National Comprehensive Cancer Network 2019 cited by 438

  22. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 1999 cited by 1,337

  23. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Frontiers in Oncology 2022 cited by 52

  24. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rohit Sharma, Joseph J. Skitzki, Emily Smith, Katy K. Tsai, Evan Wuthrick, Yan Xing, Nicole R. McMillian, Sara Espinosa - Journal of the National Comprehensive Cancer Network 2024 cited by 125